Medical Device News Magazine

Pulmonary Fibrosis Foundation Urges Patients to Use Only FDA-Approved Oxygen Delivery Devices

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

The medical advisory board of the Pulmonary Fibrosis Foundation (PFF), the nation’s leading pulmonary fibrosis (PF) research, education, and advocacy organization, has issued a position statement on non-prescription supplemental oxygen.

The statement advises the patient community to use only FDA approved oxygen delivery devices as prescribed by their doctor. Individuals should not purchase an oxygen supply device without a prescription from a healthcare provider because doing so may lead to serious health problems. In addition, non-FDA approved oxygen delivery systems may not reliably deliver oxygen.

“Supplemental oxygen therapy is necessary and beneficial to many people living with PF. Oxygen users often prefer portable oxygen concentrators (POC) so they can remain active and mobile. Unfortunately, existing POCs have limitations such as short battery life and inadequate oxygen flow,” said Dr. Amy Hajari Case, Senior Medical Advisor for Education and Awareness for the PFF. “However, non-FDA approved portable oxygen concentrators available online are not the solution. Patients should always speak with their healthcare provider before any out-of-pocket purchase of a portable oxygen concentrator.”

The PFF’s medical advisory board is committed to helping patients who rely on supplemental oxygen. In February, the PFF joined with 23 other patient, professional, and industry groups to advocate for patient-centric legislative changes to supplemental oxygen supply and reimbursement. The PFF’s efforts to advocate for improvements in access to oxygen are ongoing.

To review the full PFF statement on Non-prescription Supplemental Oxygen, click here.

More than 250,000 Americans are living with pulmonary fibrosis and interstitial lung disease, progressive diseases that cause inflammation, scarring, or both, that damage the lung’s capacity to transfer vital oxygen from the air into the blood. Over 50,000 new cases are diagnosed each year. There is no known cure, but many clinical trials are underway.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.

ArisGlobal Reports | Newest Version of LifeSphere® Regulatory Platform Launches

Ann-Marie Orange, CIO & Global Head of R&D shares, “With more than 35 years of experience in life sciences technology, ArisGlobal is the only technology company offering strong Safety, Regulatory, and Quality Management solutions powered with next-generation cognitive computing, delivering unmatched interoperability across the R&D IT ecosystem. Over the last 18 months ArisGlobal has made significant investment in the strategic acquisitions of Amplexor Life Sciences and SPORIFY, along with technology R&D – and we’re not stopping.”